Esophagus Cancer Clinical Trials 2023

What are the top hospitals conducting esophagus cancer research?

When it comes to cutting-edge clinical trials in the battle against esophagus cancer, several esteemed hospitals are leading the charge. In Houston, the M D Anderson Cancer Center takes the forefront with an impressive 13 ongoing trials dedicated to this challenging condition. Over its history, M D Anderson has contributed to a total of 24 esophagus cancer trials since recording its first trial back in 2003. Moving eastward to New york City, Memorial Sloan Kettering Cancer Center is making significant strides as well. With seven active esophagus cancer trials and a cumulative record of 23 studies, their commitment can be traced back to their earliest recorded trial in 2002.

Heading further north to Saint Louis, Washington University School of Medicine continues its dedication with six active clinical trials for esophagus cancer and a commendable track record of 18 previous studies since initiating their first recorded trial in 2005. On the west coast, the University of California Davis Comprehensive Cancer Center joins this prestigious list by currently conducting five active esophagus cancer trials while having completed eight prior investigations dating back to their inaugural trial in 2011. Similarly on the East Coast at University of Pittsburgh Cancer Institute (UPCI), they have also been actively contributing through five ongoing clinical tests for esophageal conditions; having achieved additional eight examinations since commencing investigation particularly from year2010.

These renowned institutions represent shining beacons of hope for those affected by esophagus cancer and demonstrate incredible advancements made within medical research nationwide. The collective efforts exerted by these top hospitals underscore that every step taken towards understanding this complex disease brings us closer toward improved treatment options and outcomes for patients around the world

Which are the best cities for esophagus cancer clinical trials?

When it comes to esophagus cancer clinical trials, several cities emerge as leading centers for research and treatment options. Houston, Texas leads the way with 30 ongoing trials focusing on various treatments like proton beam radiation therapy, pembrolizumab, and other potential breakthroughs. New york City follows closely behind with 23 active trials examining BMS-986340, different treatment approaches, and pembrolizumab. Los Angeles also plays a significant role in esophagus cancer research with 19 ongoing trials investigating targeted therapies such as Subprotocol C2 (MET exon 14 deletion/mutation), pembrolizumab, berzosertib, among others. These cities showcase their dedication to advancing knowledge and improving outcomes for individuals affected by esophagus cancer through innovative clinical trials.

Which are the top treatments for esophagus cancer being explored in clinical trials?

When it comes to exploring novel treatments for esophagus cancer, clinical trials have shed light on several promising options. At the forefront is pembrolizumab, a well-studied drug currently under investigation in three active trials dedicated to esophagus cancer since its first listing in 2014. Joining this contender is atezolizumab, which has shown potential with two ongoing trials and four all-time studies since being introduced in 2017. Additionally, radiation therapy continues to be explored as an effective treatment option through three active and eighteen all-time esophagus cancer trials since 2002. Finally, a pharmacological study stands out with three current investigations and five total past trials starting from its inception in 2010. These advancements bring hope for improved interventions against esophagus cancer that can make a meaningful difference in patients' lives.

What are the most recent clinical trials for esophagus cancer?

Exciting advancements are being made in the field of esophagus cancer research, with recent clinical trials shedding light on potential breakthroughs. Among these trials is a Phase 2 study investigating the combination of futibatinib, pembrolizumab, and chemotherapy for esophagus cancer patients. Another Phase 1 trial focuses on CA-4948 as a potential treatment option for this type of cancer. Furthermore, a Phase 1/Phase 2 study explores CBP-1019 both as monotherapy and in dose escalation for early-stage esophagus cancer. Additionally, promising results have emerged from a Phase 2 trial involving Devimistat combined with other drugs like HCQ and Gemcitabine. Lastly, another Phase 2 trial examines the efficacy of mFOLFOX6 along with pembrolizumab and propranolol to combat esophageal cancer. These ongoing studies offer hope for improved treatment strategies against this challenging disease.

What esophagus cancer clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of esophagus cancer research. One noteworthy trial, sponsored by EMD Serono Research & Development Institute, Inc., investigated the potential of M1231 and was completed in January 2021. Additionally, City of Hope Medical Center concluded a trial studying Pembrolizumab in April 2019. Notably, Sidney Kimmel Cancer Center at Thomas Jefferson University conducted a Fine-Needle Aspiration study that ended in September 2018. These trials and others carried out by renowned institutions such as M.D. Anderson Cancer Center, Duke University, Merck Sharp & Dohme LLC, and Dana-Farber Cancer Institute shed light on new treatment possibilities for esophagus cancer patients.